Sep

12

Remarkable supplement made from phytoplankton. Is it to good to be true?

Filed Under Advanced Diet Advice | Leave a Comment

Thanks to a chance discovery, marine phytoplankton - the food source of the ocean�s most powerful mammals - is now available as a human health food in the UK.

This remarkable story begins when Tom Harper, an American sea farmer who came close to death with a rare form of cancer, decided to eat the phytoplankton he grew for his ocean dwelling livestock, shocking medics when they recently gave him the �all clear�.

Having fallen ill, Mr Harper took half a teaspoon of phytoplankton paste daily and soon noticed some relief with his pain. Then surgeons hoping to prolong Tom�s life with a specialised procedure found an unusual development - his numerous tumours were benign.

Understandably, news of Tom�s miraculous recovery spread rapidly around the world and as daughter Tiffany reports: �We�ve had calls from all over the States, Asia and the UK. This is a product that is in huge demand from people within the medical system, holistic healing and people who are taking a stand around their health.�

Phytoplankton is a staple foodstuff for whales who can live for well over 100 years. The plankton eating Whale Shark for example can reach 150 years, growing up to 14 metres long, weighing around 15 tons and remaining sexually active until it dies. Thanks to Tom and his remarkable discovery, the nutritional secret of these mammals is now available on shore.

A far cry from Tom�s original paste however, which specialist Rowan Haigh describes as �a quick and easy way to extract all the nutrients�, the phytoplankton is now available in the UK in a liquid supplement called OceanFarmaSea manufactured by US firm ForeverGreen.

Tom Harper wholeheartedly believes that the phytoplankton is behind his amazing recovery as well as weight loss and a lowering of blood sugar levels. �In six months, I no longer required insulin and can now eat just about what I want. I feel fabulous.� Says Tom.

Attempting to unravel this health phenomenon, Dr Bob Rowe thinks that phytoplankton is able to affect health at the deepest cellular level in the body by influencing the transmission of nutrition and regulating blood sugar levels. He came across phytoplankton when one of his clients managed to heal a seemingly incurable case of dandruff in days.

�It makes sense that having depleted the quality of our soils with intensive farming, we are now turning our attention to the oceans.� Says Carl Munson, a natural health practitioner and phytoplankton fan. �I�ve been waiting for a super food like this, which contains some of the finest health-enhancing ingredients known to man such as aloe vera, noni juice and mangosteen. It also features the added benefits of frankincense and the powerful sea algae Astaxanthin.�

�It�s such a valuable contribution to all-round good health and I am reassured to know that Tom�s production process actually causes a net increase in the phytoplankton population, rather than depleting it.� Adds Carl.

Jacques Cousteau, the intrepid undersea explorer once said �the future of nutrition is found in the ocean�. It seems he was absolutely right.

Sep

8

Soy Protein Reduces Effects Of Diabetes On Liver

Filed Under Advanced Nutritional Supplements | Leave a Comment

Soy Protein Reduces Effects Of Diabetes On Liver

Bethesda, MD — A group of researchers from Mexico has discovered that a diet rich in soy protein may alleviate fatty liver, a disease which often accompanies diabetes. The details of their findings appear in the September issue of the Journal of Lipid Research, an American Society for Biochemistry and Molecular Biology journal.

The high levels of insulin and insulin-resistance that accompany diabetes are often associated with fatty liver or hepatic steatosis, an untreatable condition that can lead to chronic liver disease and death. In this condition, large lipid-filled compartments accumulate in the cells of the liver due to an increase in production of fatty acids in the liver. The end result is an enlarged liver.

Following up research that indicated that eating soy protein reduces lipid production and prevents hyperinsulinemia (the loss of effectiveness of insulin), Dr. Nimbe Torres, of the Instituto Nacional de Ciencias Medicas y Nutricion in Mexico, investigated the effects of a diet high in soy protein on the development of fatty liver associated with diabetes.

Dr. Torres fed Zucker diabetic fatty rats that develop hyperinsulinemia and hepatic steatosis a diet of soy protein for 160 days. She found that the consumption of soy protein prevented the accumulation of triglycerides and cholesterol in the liver despite the development of obesity and hyperinsulinemia in the rats.

“We also observed that the effects of soy protein were due to a low expression of genes involved in the synthesis of fatty acids and triglycerides in the liver,” explained Dr. Torres. “These changes were due to a reduction in the transcription factors that control the expression of genes involved in lipid production.”

In addition, levels of a transcription factor involved in controlling genes involved in fatty acid breakdown, as well as its target genes, were increased in rats fed soy protein. Thus, feeding rats a soy-rich diet reduced the amount of fatty acid in their liver by not only reducing lipid production but also by increasing its breakdown.

Although further research is needed, Dr. Torres believes that consuming soy protein could very well reduce insulin resistance, renal damage, and fatty liver, improving quality of life.

Sep

8

Manhattan Pharmaceuticals Obesity Drug Safe in Phase Ia Study

Filed Under Diet Buzz > Trends, Fads, Hype, and More | Leave a Comment

Manhattan Pharmaceuticals Obesity Drug Safe in Phase Ia Study
Prior Animal Studies Suggest This Experimental Drug Resets The Brain’s ‘Appetite Meter’

NEW YORK, Sept. 7, 2005 (PRIMEZONE) — Manhattan Pharmaceuticals, Inc. (OTCBB:MHTT) said Oleoyl-estrone, its experimental obesity drug, was shown to be safe with no serious adverse events noted in a Phase Ia study of 36 obese volunteers.

The results were announced this morning at the Oppenheimer & Co. Diabetes Conference at the Warwick Hotel during a presentation by Manhattan’s chief executive officer, Douglas Abel.

The dose-escalating study was conducted to measure the pharmacokinetic profile of Oleoyl-estrone (OE), as well as its safety and tolerability in obese males and females. Twelve of the 36 patients received placebo and 24 received a single dose of OE in one of six strengths ranging from 1mg to 150mg.

A follow-on study, a Phase Ib, will assess the drug’s safety and tolerability in 24 obese volunteers in four cohorts of six patients each receiving either placebo or OE in doses ranging from 10mg to 150mg for seven consecutive days. The company anticipates releasing additional data from these studies in the early Fall.

OE is an orally administered small molecule that lowers the appetite setting in the brain’s ponderostat, decreasing food intake without affecting energy expenditure. It has been shown to cause significant weight loss in extensive preclinical studies with lean and obese animals, even in the presence of abundant food and water.

Obesity is one of the most common metabolic disorders in the world. Nearly 61 percent of all Americans are considered to be overweight, and 26 percent are considered to be obese. The World Bank estimates that obesity alone accounts for more than 12 percent of the U.S. national health care budget. The National Institutes of Health estimated that direct costs for the treatment of obesity in 1988 were in excess of $45 billion and accounted for nearly ten percent of the total national cost of health care; a decade later, annual direct costs for the treatment of obesity had risen to $102 billion. As these statistics illustrate, obesity is a rapidly growing, costly disease for which there is currently no effective treatment. Moreover, diet and physical exercise regimens are difficult to maintain. As a result, most overweight patients can lose only moderate amounts of weight, and usually only for a short period of time. The current medications for the treatment of obesity have significant side effects that limit their use.

Manhattan believes that a safe, effective, orally administered compound that not only produces, but also sustains weight loss would be a breakthrough in the treatment of obesity, and would represent a significant advantage over currently available treatments. The company estimates that the future market opportunity is in the multi-billions of dollars range, given the number of individuals in the U.S. suffering from obesity and the rapid growth of the problem globally.

Sep

4

Kettlebells Are a Sinister Russian Weight Training Device

Filed Under No Holds Barred Weight Training | Leave a Comment

Kettlebells made popular by Pavel Tsatsouline a former physical training instructor for the Soviet Special Forces are cast iron weights that look like a cannon ball with a handle. An ancient Russian exercise device, the Kettlebell has long been a favorite for those seeking a special edge in strength and endurance.

Both the Soviet Special Forces and numerous world-champion Soviet Olympic athletes used the ancient Russian Kettlebell as their secret weapon for extreme fitness. Thanks to the kettlebells’s astonishing ability to turbocharge physical performance, these Soviet supermen creamed their opponents time-and-time-again, with inhuman displays of raw power and explosive strength.

Training with kettlebells will push your body to the limits due to the dynamic nature of the exercise your going to be hitting many of the major and minor muscle groups with one power packed workout.

— keep looking »